Treatment of female spontaneously hypertensive rats (SHR) and control Wistar-Kyoto (WKY) rats with captopril was carried out by the addition of the drug in the drinking water throughout pregnancy and lactation and after weaning. At 28 weeks of age, average systolic blood pressure of treated SHR was 113±3 mm Hg, which was below that of control SHR (188±3 mm Hg) and WKY rats (124±3 mm Hg). Body weight and heart rate of the SHR were not affected by the treatment Tissue level of catecholamines was increased by captopril treatment in the superior cervical ganglia but remained unchanged in the plasma, heart, mesenteric arteries, and the adrenal glands of both SHR and WKY rats. Left ventricular weight, wall thickness, and internal diameter of the left ventricle in the SHR were reduced by the treatment Morphometric measurements of the mesenteric arteries showed that vascular alterations present in the control SHR were prevented by the treatment In the superior mesenteric artery and large mesenteric artery, smaller lumen size at maximal relaxation found in the control SHR was normalized to the level of the WKY rats. Hypertrophy of the medial wall in the superior mesenteric, large and small mesenteric arteries, and an increase in the number of smooth muscle cell layers in the large mesenteric artery of the SHR were prevented by the treatment. Perfusion study of the mesenteric vascular bed showed that reactivity of these vessels to norepinephrine was reduced, and sensitivity to norepinephrine (as determined by the effective dose that causes 50% of maximal response) was increased in the SHR by captopril treatment Sensitivity of the tail artery in response to norepinephrine was not altered by the treatment We conclude that long-term treatment with captopril of SHR before and after birth prevented the development of hypertension, structural and functional alterations of the mesenteric arteries, and cardiac hypertrophy. (Hypertension 1991;17:141-150) C hronic intracerebroventricular administration of captopril, when started in young spontaneously hypertensive rats (SHR), has been shown to attenuate the development of hypertension in these animals.
C hronic intracerebroventricular administration of captopril, when started in young spontaneously hypertensive rats (SHR), has been shown to attenuate the development of hypertension in these animals.
-
2 Such an effect was associated with a marked depression in vascular reactivity to exogenous vasoconstrictors and a potentiation of baroreceptor reflex control of the heart rate.'- 3 The depressor effect on vascular reactivity was probably related to an attenuation in sympathetic vasoconstrictor tone but may also be attributed to captopril-induced attenuation in the development of structural vascular changes in the SHR. 2 Long-term treatment of 6-week-old SHR with captopril in the drinking water for 14 weeks, 4 -5 or 4,8,12, or 16 weeks, 6 prevented the development of hypertension and also caused long-lasting decreases in myocardial and aortic wall hypertrophy. 4 In the mesenteric resistance arteries, the same treatment caused a reduction in the wall/lumen ratio but an increase in the compliance and a reduction in contractile ability. 4 Similarly, long-term treatment of 4-week-old SHR with perindopril, another angiotensin converting enzyme inhibitor, for 20 weeks prevented the development of hypertension and attenuated the structural and functional alteration of the resistance vessels from the mesenteric bed. 7 Perindopril also had a dose-dependent effect on the blood pressure and resistance vessel media thickness. 7 However, in these studies withdrawal of the treatment resulted in a gradual rise in blood pressure but not to the level of the control SHR. 5 -7 Similarly, although long-term treatment of SHR from age 4 to 14 weeks with cilazapril prevented the development of hypertension, discontinuation of the treatment resulted in an increase of systolic blood pressure to control hypertensive levels within 4 days. 8 This is probably because structural alterations of the mesenteric arteries had already taken place, 9 at the time when the treatment was initiated (4 or 6 weeks old). In the SHR, hyperplasia of the smooth muscle cells in the large mesenteric arteries takes place immediately after birth, 10 leading to the changes observed in prehypertensive SHR 9 and SHR with established hypertension. 11 In this study, treatment of the SHR was started before birth and continued until 28 weeks of age. The effects of such long-term treatment on the blood pressure, cardiovascular changes, and tissue level of catecholamines were investigated.
Methods
Treatment of the SHR and normotensive WistarKyoto (WKY) rats was initiated in Birmingham, Alabama. Breeder SHR and WKY rats were purchased from virus-free colonies (Charles River Breeding Laboratories, Wilmington, Mass.). The rats were treated with captopril using a protocol that has been shown to be effective in normalizing the blood pressure of the SHR. 12 Briefly, at the time of breeding, female SHR and WKY rats were given captopril (Squibb Institute, Princeton, N.J.) in their drinking water at a dose of 100 mg/kg/day. They were maintained on this dosage throughout pregnancy and lactation. After weaning, the pups were maintained on 50 mg/kg/day captopril in their drinking water until they were 28-30 weeks old, when they were used for various studies. Only female rats were used in our studies. Beginning at 8 weeks old, body weight and systolic blood pressure of the rats were measured biweekly, the latter by indirect tail-cuff compression method in conscious animals. Control and captopril-treated female SHR and WKY rats were shipped to McMaster University at 20 weeks of age. Some of these rats were then shipped to Memorial University of Newfoundland for functional studies of the arteries.
Preparation of the Animals and Sampling of the Tissues
Systolic blood pressure and body weight of 28-30-week-old female control and captopril-treated SHR and WKY rats were measured in conscious rats 1 day before the experiment. Subsequently, the rats were anesthetized with sodium pentobarbital (45 mg/kg i.p.). The left femoral artery was cannulated for direct measurements of blood pressure and heart rate. Blood samples were obtained through a cannula inserted into the abdominal aorta. The mesenteric vascular bed was cannulated for perfusion fixation of the arteries. 11 The two ventricles of the heart were removed for weight determination. The heart, adrenal glands, a segment of superior mesenteric artery with some large mesenteric arteries, and superior cervical ganglia were removed and immediately frozen for the determination of tissue levels of catecholamines with use of an electrochemical detector in a high-performance liquid chromatography (HPLC) system, as described previously by Fields et al. 13 Briefly, tissues were removed and homogenized with a Polytron (Brinkmann Instruments, Westbury, N.Y.) in 2 ml of 0.25N acetic acid containing 3,4-dihydroxybenzylamine as a biogenic amine internal standard. After centrifugation at 5,000g for 20 minutes at 4°C, the supernatant was added to 20 mg activated alumina and 2 ml of 2M Tris buffer containing 2% EDTA (pH 8.7). The samples were shaken vigorously for 15 minutes, the supernatant was discarded, and the alumina was washed twice with 3M Tris-2% EDTA and twice with distilled water. The catecholamines were desorbed from the alumina using 0.25N acetic acid and frozen at -70°C for later assay. A 20 yl aliquot of the sample was analyzed by HPLC using an electrochemical detector. Samples were chromatographed on a reversephase, ion-paired column containing microparticulate-bound C18 as the stationary phase and 0.1 M sodium phosphate buffer (pH 3) containing 100 mg/1 sodium octyl sulphate as the mobile phase. Retention times were 3.25 minutes for norepinephrine, 4.10 minutes for epinephrine, 5.40 minutes for dihydroxybenzylamine, and 8.25 minutes for dopamine. Recovery from the alumina averaged 80-90% and overall recovery (from homogenization to final analysis) was 50-60%. Values reported were corrected for recovery of the internal standard. The lower limit of detection in the HPLC system was 2-3 pg.
Morphometry
Three categories of mesenteric arteries from 28-week-old control and captopril-treated female SHR and WKY rats, representing elastic conducting vessels (superior mesenteric), large muscular arteries (large mesenteric), and arteriolar resistance arteries (small mesenteric) were fixed by perfusion fixation at low pressure to avoid expansion of the lumen. 14 The arteries were fixed in a maximally relaxed state, using a fixation procedure that caused minimal change in smooth muscle cell volume. 11 The cross-sectional area of various components of the vessel wall was measured as described previously. 15 
Reactivity and Sensitivity Study
The age of the female control and captopriltreated SHR ranged from 28 to 30 weeks. The McGregor preparation of the mesenteric arteries, 16 consisting of cannulation of the superior mesenteric artery and perfusion of four branches of large mesenteric arteries at a constant flow rate of 4 ml/min at 37°C, was used to study the responsiveness of the mesenteric vascular bed to norepinephrine in the presence and absence of cocaine (4xlO~5 M) 1S and propranolol (lxlO" 7 M). Vascular reactivity of the tail artery from captopril-treated and control rats was also tested using a previously published technique.
Segments of tail arteries mounted between two fine tungsten wires at a resting tension of 1 g were used for tension studies and for measuring the response of the arteries to norepinephrine in the presence and absence of cocaine and propranolol. All doses were expressed as milligrams of norepinephrine per kilogram of body weight.
Statistics
Values are expressed as mean±SEM. Sample size is indicated in all tables. Student's unpaired t test was used for comparison between various experimental groups. Linear regression analysis was also used to test whether there was a correlation between blood pressure and the medial area and the number of smooth muscle cell layers. Differences were considered significant at/?<0.05.
Results

Physical Characteristics
The systolic blood pressure profiles of the SHR and WKY rats used in this study are given in Figure  1A . Blood pressure of the treated SHR was maintained within the normotensive range, below that of the control WKY rats. Beginning at 12 weeks of age, average blood pressure of treated WKY rats was also significantly lower than the control WKY rats. Captopril treatment did not affect the body weight of the SHR but lowered the body weight in the WKY rats (Table 1, Figure IB) . At 28 weeks, the body weight of the female SHR was lower than that of the corresponding WKY rats (Table 1) . Systolic blood pressure, measured using the indirect method (tail-cuff) and measured directly through the left femoral artery under anesthesia, showed that captopril treatment attenuated the blood pressure increase in both SHR and WKY rats. Blood pressure in the captopriltreated SHR was similar to that in the untreated WKY rats; however, blood pressure differences between SHR and WKY rats within each group were still maintained. Heart rate was faster in the SHR than in the WKY rats, and captopril did not affect the heart rate of SHR and WKY rats. However, the treatment did prevent the development of hypertrophy of both right and left ventricles in the SHR. In the SHR, the major axis of the left ventricle and the thickness of the left ventricle were also reduced by the treatment. The weight of the superior cervical ganglia and the adrenal glands was not affected by captopril treatment. There was no difference between SHR and WKY rats in the weight of the superior cervical ganglia and the adrenal glands.
Tissue Catecholamines
Tissue levels of catecholamines are given in Table 2 . In the control group, plasma levels of norepinephrine, epinephrine, and dopamine were elevated in SHR as compared with those in WKY rats. Captopril treatment had no effect on the plasma catecholamine levels in the SHR but elevated the level of epinephrine in the WKY rats. In both SHR and WKY rats, captopril had no effect on the tissue level of catecholamine in the heart, mesenteric artery, and adrenal glands. In the superior cervical ganglia, tissue levels of norepinephrine, epinephrine, and dopamine in the SHR were elevated, but the dopamine level in the WKY rats was reduced by captopril treatment. Among the control groups, tissue levels of norepinephrine and sometimes the levels of epinephrine as well were higher in the SHR than WKY rats in the plasma and superior cervical ganglia, but dopamine levels were higher in the WKY rats than in the SHR in the superior cervical ganglia and the mesenteric arteries. Epinephrine levels were also higher in the WKY rats than in the SHR in the mesenteric arteries. After captopril treatment, differences in norepinephrine, epinephrine, and dopamine levels between SHR and WKY rats persisted in some tissues. 
Morphometry
Superior mesenteric artery. In both control and captopril-treated groups, the total cross-sectional area (CSA) of the vessel wall was similar between the SHR and WKY rats; captopril treatment reduced the CSA of the total vessel wall in the WKY rats with no apparent effect on the SHR (Table 3) . However, the luminal area in the SHR at maximal relaxation was smaller than that in the WKY rats, indicating that these arteries were smaller in the SHR than in the WKY rats. Normalization of the vessel wall with the lumen (i.e., wall/lumen ratio) actually showed that the vessel wall in the SHR was hypertrophied due to larger CSA of the media and adventitia. At the magnification (xl35) at which the measurements were made for this category of vessels, the intimal layer was barely visible and therefore cannot be measured accurately. Intimal area was included with the medial measurements. Captopril treatment lowered the media/lumen ratio in the SHR to the same value as that of the WKY rats, with minimal effect on the WKY rats. The number of smooth muscle cell layers in the control SHR and WKY rats was similar, and captopril Large mesenteric artery. Total CSA of the vessel wall was similar between SHR and WKY rats in both groups of rats (Table 3) . CSA of the lumen at maximal relaxation showed that large mesenteric arteries from the SHR were actually smaller than those in the WKY rats (Figure 2) . Normalization of the CSA of the vessel wall with lumen showed that the vessel wall in the SHR was hypertrophied, mainly due to larger medial area. The number of smooth muscle cell layers in the media was also higher in the SHR than WKY rats. Captopril treatment reduced the size of the medial wall in the SHR to the same size as that of control WKY rats. The number of smooth muscle cell layers was also reduced by the treatment in the SHR to a similar number as that in the untreated WKY rats, whereas such an effect was absent in the WKY rats. Correlation of the blood pressure with the CSA of the media and the number of smooth muscle cells in the media showed a positive n = 10 each for untreated spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats; nine each for treated SHR and WKY rats. NE, norepinephrine; E, epinephrine; DA, dopamine. correlation (r=0.58 and 0.75, respectively; p<0.001) among these variables.
Small mesenteric artery. In this group of vessels, despite the fact that sampling of the arteries was carried out by the same person from predetermined sites in the vascular bed, 11 there were still variations in the size of the vessel within the same group of rats. Therefore, even though CSA of the total vessel wall and lumen were similar between SHR and WKY rats, normalization of the vessel wall with lumen (i.e., wall/lumen ratio) showed that the small mesenteric arteries were hypertrophied in the SHR due to larger CSA of intima and media, as indicated by larger intima/lumen and media/lumen ratios (Table 3 ). In the media, the number of smooth muscle cell layers was similar between SHR and WKY rats. Treatment significantly reduced the ratios of various vessel wall components to the lumen in both SHR and WKY rats, but more in the SHR than in the WKY rats to the extent that after the treatment, the difference between SHR and WKY rats in the intima-to-lumen and media-to-lumen ratios was eliminated. However, the treatment had no effect on the number of smooth muscle cell layers in the SHR but reduced the adventitia/lumen ratio by a different magnitude in the SHR as compared with WKY rats, resulting in differences between SHR and WKY rats after captopril treatment. Correlation of the blood pressure with CSA of the media and the number of medial smooth muscle cell layers showed a significant correlation (r=0.83, 0.60, and/?<0.001 and 0.01, respectively) among these variables.
Reactivity and sensitivity study. Reactivity of the mesenteric vascular bed, as measured by the maximal pressure development of the bed to the agonist norepinephrine, showed that treatment of the SHR with captopril lowered the reactivity of the vascular bed to norepinephrine (Table 4) . Sensitivity of the vascular bed to norepinephrine, as indicated by the effective dose that causes 50% of maximal response (ED-H), showed that the treatment had reduced the sensitivity of the tissue to norepinephrine. Pretreatment of the vascular bed with cocaine to block the neuronal reuptake of norepinephrine and with propranolol to block the /3-response of the tissue showed no significant effect on the reactivity of the tissue to norepinephxine, although sensitivity of the tissue to norepinephrine was enhanced. In the tail artery, sensitivity of the tissue to norepinephrine was not affected by captopril treatment. Pretreatment of the arteries with cocaine and propranolol caused a similar shift to the left of the dose-response curves of the arteries from control and captopril-treated SHR to norepinephrine (Figure 3 ).
Discussion
The main finding in this study is that long-term treatment of the SHR with captopril, when initiated
WKY-C SHR-C SHR-T FIGURE 2. Light micrographs of large mesenteric arteries from control (C) and treated (T) spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats. Note the difference in lumen size among the four vessels. Magnification X210. For all micrographs, bar=100 \j/n.
in utero, is effective in preventing not only the development of hypertension but also structural alterations of the heart and mesenteric arteries. It is possible that prevention of hypertension in the SHR was through treatment that prevented cardiovascular changes, as discussed below. In previous studies on the effect of antihypertensive therapies on vascular changes, the results have been variable. In most of these studies, although the expression of hypertension in the SHR was prevented by long-term treatment with one or a combination of drugs, the effect on vascular changes was minimal, and withdrawal of the treatment often resulted in rebound hypertension, usually within a few days or a few weeks. 18 - 20 In instances where permanent prevention of hypertension was achieved, Numbers in parentheses refer to either the number of animals used (mesenteric bed) or the number of tissues (tail artery). MPD, maximal pressure development (mm Hg); ED50, dose required (in mg norepinephrine/kg rat) to evoke half-maximal response (xlO~6 M). such as that obtained with neonatal destruction of the sympathetic nervous system with antiserum to nerve growth factor, 21 or with a combination of antinerve growth factor and guanethidine, 15 vascular changes that were usually present in the SHR were also prevented. 15 This is because of the important role played by the sympathetic nervous system in the initiation of hypertension and its trophic influence on the vasculature before the development of hypertension. 15 - 22 However, neonatal destruction of the sympathetic nervous system may have other side effects besides its influence on the development of the cardiovascular system.
Captopril treatment allows an alternative method of investigating the influence of the sympathetic nervous system on hypertension development and vascular changes because of its well-established sympathoinhibitory effect on the vascular system.
23
- 25 In the SHR, captopril causes a prejunctional inhibition of norepinephrine release in response to sympathetic stimulation, and this effect is selective for the vasculature. 23 The attenuation of sympathetic function has been attributed primarily to the prevention of angiotensin II formation, so that the facilitative effect of angiotensin II on noradrenergic neurones is removed. 2325 The mechanisms through which such facilitative action may take place include increased synthesis of norepinephrine, increased release of norepinephrine, blockade of neuronal uptake of norepinephrine, and enhancement of the postjunctional effects of norepinephrine, 25 some or all of which may have a trophic influence on the development of vascular changes in the SHR.
With the exception of the superior cervical ganglia, where captopril treatment increased the tissue levels of catecholamine, we found that captopril did not alter catecholamine levels in the plasma, heart, mesenteric arteries, and adrenal glands of either SHR or WKY rats. Cerebroventricular treatment of 7-weekold SHR with captopril for 4 weeks also did not alter the basal plasma levels of norepinephrine and epinephrine. 26 Therefore it is clear that captopril treatment does not affect the synthesis of norepinephrine in these tissues. However, under in vivo conditions it is possible that other sympathoinhibitory effects of captopril, such as inhibition of angiotensin II effect on norepinephrine release, blockade of neuronal uptake of norepinephrine, and postjunctional effects of norepinephrine, may still be present, so that trophic influence of the sympathetic nervous system on cardiovascular changes will be affected by captopril treatment. Further study is needed to clarify the role of the sympathetic nervous system after angiotensin converting enzyme inhibition in the prevention of cardiovascular changes.
Cardiac hypertrophy, present in the control SHR as compared with control WKY rats, was prevented by captopril treatment, which is in agreement with previous studies where treatment of young (6-weekold) 5 and adult (10-14-week-old) 27 SHR with captopril decreased the heart weight. In these two studies, normalization of the heart weight was directly correlated to the duration of the treatment, in that reduction to the level of untreated WKY rats was achieved after 6 months of treatment. 27 However, from these studies, including our present study, it is not possible to determine whether reversal or prevention of cardiac hypertrophy was due to the blood pressurelowering effect or sympathoinhibitory effect of captopril. Both mechanisms may be involved. In the SHR, blood pressure lowering and blockade of adrenergic influences are independent variables that have been shown to be involved in the prevention or reversal of cardiac hypertrophy. 28 Cardiac hypertrophy in the SHR was probably both concentric, as indicated by increased wall thickness, and eccentric, as suggested by the increase in the major axis of the left ventricle.
The effect of captopril treatment on the structure of the mesenteric arteries appears to be different depending on the type of the vessels. In the superior mesenteric artery, an elastic conducting vessel, captopril treatment prevented the hypertrophy of the vessel wall in the SHR. The medial area was maintained at the same level as that of WKY rats, and the treatment had minimal effect on the number of smooth muscle cell layers. This is probably because in this vessel vascular changes are mainly due to hypertrophy of the medial smooth muscle cells, which in turn is secondary to the development of hypertension, 29 so that prevention of hypertension by captopril also prevented smooth muscle cell hypertrophy. These results are consistent with those obtained in the aorta of SHR, another elastic conducting vessel. Long-term treatment of young SHR with captopril has been shown to reduce the wall/lumen ratio of the aorta 4 and has been shown to prevent the development of smooth muscle cell polyploidism and medial hypertrophy. 30 It is not known whether the prevention of smooth muscle cell hypertrophy by captopril is also related to the inhibition of angiotensin II forma-tion. Studies using cultured aortic smooth muscle cells showed that angiotensin II induces hypertrophy but not hyperplasia of cultured rat aortic smooth muscle cells. 31 In the large mesenteric artery, a muscular reactive vessel, captopril treatment also reduced the medial wall in the SHR to the same size as that of the WKY rats. More importantly, the number of smooth muscle cell layers was reduced to the same number as that in the untreated WKY rats. This was similar to the results when SHR were sympathectomized after birth with antinerve growth factor and guanethidine. 15 It is unlikely that prevention of medial wall hypertrophy by captopril treatment in this type of vessel was due to the elimination of direct action of angiotensin II on the vascular smooth muscle, because in the muscular and resistance vessels from the mesenteric bed of SHR, the incidence of polyploid (i.e., hypertrophied) smooth muscle cells was similar to that of WKY rats. 32 In these vessels, increase in medial wall size is mainly due to hyperplasia of the smooth muscle cells. 33 As discussed above, angiotensin II is known to induce hypertrophy and not hyperplasia of vascular smooth muscle cells. It is also unlikely that prevention of vascular changes in this type of artery was secondary to the prevention of hypertension by captopril because long-term treatment of SHR with vasodilators, although it normalized the blood pressure, was not sufficient to alter the vessel wall dimensions in the renal 20 and mesenteric 34 vascular beds. It is therefore possible that prevention of vascular changes in the large mesenteric arteries by captopril treatment was due to the sympathoinhibitory action of captopril on the vessel wall. In agreement with this are the observations of an increased nerve density, an increased tissue content of norepinephrine, an increased release of norepinephrine in response to nerve stimulation, and increased sympathetic nerve activity in various vascular beds (including mesenteric) of young and older SHR as compared with WKY rats (see Reference 22 for review).
In the small mesenteric artery, captopril treatment again decreased the intimal and medial area in the SHR to the same level as that of WKY rats without a significant effect on the number of smooth muscle cell layers. These results are in agreement with previous studies, which showed that treatment of young SHR with captopril 4 or perindopril 7 increased the compliance and decreased the vessel stiffness and wall/lumen ratio of small resistance vessels in the SHR.
Results from the reactivity study in the perfused mesenteric arterial preparation showed that captopril treatment lowered the maximal pressure development ability of the bed in response to norepinephrine, which agrees with the morphometric results showing reduced medial mass due to treatment. However, part of this decreased response may be related to reduced sensitivity of the arteries to norepinephrine because of the higher ED W in the captopril-treated group. Cerebroventricular administration of captopril to 6-week-old male SHR for 4 weeks also reduced the reactivity of the renal vascular bed, increased the ED 16 and EDso, and lowered basal vascular resistance. 3 In contrast, we found that sensitivity of the tail artery to norepinephrine was not affected by the treatment. This was similar to the results obtained in the resistance vessels from SHR treated with captopril for 14 weeks beginning at 6 weeks of age. 4 Comparison of the morphometric results obtained in this study on female SHR and WKY rats with our previous results on male SHR and WKY rats of similar age 11 ' 15 showed some interesting differences between the two sexes. In male SHR, the lumen area of the mesenteric arteries at maximal relaxation was similar to WKY rats in the three categories of arteries studied. 11 In this study, lumen area in the superior mesenteric artery and large mesenteric artery of female SHR at maximal relaxation was actually smaller than that in WKY rats, so that there was a remodeling of these arteries, which resulted in the encroachment of the vessel wall on the lumen, a concept introduced originally to describe a similar situation in the cerebral arterioles in stroke-prone SHR. 35 It is possible that in the female SHR, a remodeling of the mesenteric arteries has taken place as compared with WKY rats during development, so that the lumen size in the superior mesenteric arteries and large mesenteric arteries was reduced, with no change in total CSA of the vessel wall. The consequence is a thicker vessel wall, which will increase the reactivity of the vessels in response to agonists. Captopril treatment somehow prevented the remodeling of the superior and large mesenteric arteries in the female SHR during development because narrowing of the lumen was prevented by the treatment. It is not clear why such remodeling was present in the female and not in the male SHR.
In summary, we have demonstrated that chronic neonatal treatment of the SHR with captopril prevented the development of hypertension, structural and functional changes in the mesenteric arteries, and cardiac hypertrophy. The prevention of hypertension was probably manifested through the sympathoinhibitory action of captopril on the cardiovascular system, interfering with the trophic influence of the sympathetic nervous system on the development of cardiovascular changes. However, other factors, such as lowering of the blood pressure and inhibition of angiotensin II synthesis, are probably also involved in the prevention of cardiovascular changes in the SHR.
